• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report
 

Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report

on

  • 271 views

Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report @ http://www.researchmoz.us/personalized-medicine-in-oncology-partnering-terms-and-agreements-report.html

Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report @ http://www.researchmoz.us/personalized-medicine-in-oncology-partnering-terms-and-agreements-report.html

Statistics

Views

Total Views
271
Views on SlideShare
271
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

     Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report Personalized Medicine in Oncology Partnering Terms and Agreements:Industry Analysis Report Document Transcript

    • Personalized Medicine in Oncology Partnering Terms and Agreements The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of personalized medicine in oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in personalized medicine in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in personalized medicine in oncology partnering. The chapter also includes examples case studies of recent deals in personalized medicine in oncology partnering. Chapter 3 provides a review of the leading personalized medicine in oncology deals since 2007. Deals are listed by headline value signed by all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive and detailed review of personalized medicine in oncology partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances. The report also includes numerous tables and figures that illustrate the trends and activities in personalized medicine in oncology partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of personalized medicine in oncology technologies and products. Report scope Personalized Medicine in Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide. Personalized Medicine in Oncology Partnering Terms and Agreements includes: Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2007 Analysis of personalized medicine in oncology deal structure Case studies of real-life personalized medicine in oncology deals Access to over 600 personalized medicine in oncology deals The leading personalized medicine in oncology deals by value since 2007 Most active personalized medicine in oncology dealmakers since 2007 The leading personalized medicine in oncology partnering resources In Personalized Medicine in Oncology Partnering Terms and Agreements , the available contracts are listed by: Headline value Stage of development at signing Deal component type Specific therapy target Specific technology target Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. table Of Content: executive Summary chapter 1 – Introduction chapter 2 – Trends In Personalized Medicine In Oncology Dealmaking 2.1. Introduction 2.2. Personalized Medicine In Oncology Partnering Over The Years 2.2.1 Biomarker In Oncology Partnering Over The Years 2.2.2 Companion Diagnostic In Oncology Partnering Over The Years 2.2.3 Pharmacogenomics In Oncology Partnering Over The Years 2.3. Big Pharma Personalized Medicine In Oncology Dealmaking Activity 2.3.1 Big Pharma Biomarker, Companion Diagnostic And Pharmacogenomics In Oncology Dealmaking Activity 2.4. Most Active In Personalized Medicine In Oncology 2.5. Personalized Medicine In Oncology Partnering By Deal Type 2.5.1 Biomarker Partnering In Oncology By Deal Type 2.5.2 Companion Diagnostic In Oncology Partnering By Deal Type 2.5.3 Pharmacogenomics In Oncology Partnering By Deal Type 2.6. Personalized Medicine Partnering By Oncology Disease Type 2.6.1 Biomarker Partnering By Oncology Disease Type 2.6.2 Companion Diagnostic Partnering By Disease Type 2.6.3 Pharmacogenomics Partnering By Oncology Disease Type 2.7. Personalized Medicine In Oncology Partnering By Stage Of Development 2.8 Average Deal Terms For Personalized Medicine In Oncology 2.8.1 Personalized Medicine In Oncology Headline Values 2.8.2 Personalized Medicine In Oncology Upfront Payments 2.8.3 Personalized Medicine Milestone Payments 2.8.4 Personalized Medicine In Oncology Royalty Rates 2.9. The Anatomy Of Personalized Medicine In Oncology Partnering 2.9. The Anatomy Of A Personalized Medicine In Oncology Deal Personalized Medicine in Oncology Partnering Terms and Agreements
    • 2.9.a. Case Study 1: Astrazeneca, Isis Pharmaceuticals- December 07 2012 2.9.b. Case Study 2: Trovagene- Columbia University: December 11, 2011 chapter 3 – Leading Personalized Medicine In Oncology Deals 3.1. Introduction 3.2. Top Personalized Medicine In Oncology Deals By Value chapter 4 – Big Pharma Personalized Medicine In Oncology Deals 4.1. Introduction 4.2. How To Use Big Pharma Partnering Deals 4.3. Big Pharma Personalized Medicine In Oncology Partnering Company Profiles abbott amgen astellas astrazeneca bayer biogen Idec boehringer Ingelheim bristol-myers Squibb celgene eisai eli Lilly gilead Sciences glaxosmithkline johnson & Johnson merck & Co merck Kgaa novartis pfizer roche sanofi servier teva chapter 5 – Personalized Medicine In Oncology Dealmaking Directory 5.1. Introduction 5.2. Company A-z 5.3. By Stage Of Development discovery marketed phase I phase Ii phase Iii preclinical regulatory 5.4. By Deal Type asset Purchase assignment bigpharma Outlicensing co-development collaborative R&d co-market contract Service co-promotion crada development distribution equity Purchase evaluation grant joint Venture licensing manufacturing marketing option Personalized Medicine in Oncology Partnering Terms and Agreements
    • promotion research spin Out sub-license supply technology Transfer termination 5.5. By Oncology Therapy Area oncology chapter 6 – Personalized Medicine In Oncology Dealmaking Directory By Specific Technology Type personalised Medicine pharmacogenomics biomarkers companion Diagnostics chapter 7 –partnering Resource Center 7.1. Online Personalized Medicine In Oncology Partnering 7.2. Personalized Medicine Partnering Events 7.3. Further Reading On Personalized Medicine Dealmaking recent Report Titles From Currentpartnering order Form – Reports order Form – Therapy Reports ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Personalized Medicine in Oncology Partnering Terms and Agreements